168 related articles for article (PubMed ID: 18190686)
21. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?
das Neves J; Amiji M; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(4):389-99. PubMed ID: 21506290
[TBL] [Abstract][Full Text] [Related]
22. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
23. Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.
Catalone BJ; Miller SR; Ferguson ML; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
Biomed Pharmacother; 2005 Sep; 59(8):430-7. PubMed ID: 16154721
[TBL] [Abstract][Full Text] [Related]
24. Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety.
Lozenski K; Ownbey R; Wigdahl B; Kish-Catalone T; Krebs FC
BMC Pharmacol Toxicol; 2012 Oct; 13():9. PubMed ID: 23025553
[TBL] [Abstract][Full Text] [Related]
25. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques.
Cole AM; Patton DL; Rohan LC; Cole AL; Cosgrove-Sweeney Y; Rogers NA; Ratner D; Sassi AB; Lackman-Smith C; Tarwater P; Ramratnam B; Ruchala P; Lehrer RI; Waring AJ; Gupta P
PLoS One; 2010 Nov; 5(11):e15111. PubMed ID: 21124745
[TBL] [Abstract][Full Text] [Related]
26. Comparative safety evaluation of the candidate vaginal microbicide C31G.
Catalone BJ; Kish-Catalone TM; Neely EB; Budgeon LR; Ferguson ML; Stiller C; Miller SR; Malamud D; Krebs FC; Howett MK; Wigdahl B
Antimicrob Agents Chemother; 2005 Apr; 49(4):1509-20. PubMed ID: 15793133
[TBL] [Abstract][Full Text] [Related]
27. High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides.
Vincent KL; Bourne N; Bell BA; Vargas G; Tan A; Cowan D; Stanberry LR; Rosenthal SL; Motamedi M
Sex Transm Dis; 2009 May; 36(5):312-8. PubMed ID: 19295469
[TBL] [Abstract][Full Text] [Related]
28. Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo.
Scott YM; Park SY; Dezzutti CS
Antimicrob Agents Chemother; 2016 Feb; 60(2):904-12. PubMed ID: 26596954
[TBL] [Abstract][Full Text] [Related]
29. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro.
O'Connor TJ; Kinchington D; Kangro HO; Jeffries DJ
Int J STD AIDS; 1995; 6(4):267-72. PubMed ID: 7548290
[TBL] [Abstract][Full Text] [Related]
30. The importance of the vaginal delivery route for antiretrovirals in HIV prevention.
Ferguson LM; Rohan LC
Ther Deliv; 2011 Dec; 2(12):1535-50. PubMed ID: 22468220
[TBL] [Abstract][Full Text] [Related]
31. Safety and anti-HIV assessments of natural vaginal cleansing products in an established topical microbicides in vitro testing algorithm.
Lackman-Smith CS; Snyder BA; Marotte KM; Osterling MC; Mankowski MK; Jones M; Nieves-Duran L; Richardson-Harman N; Cummins JE; Sanders-Beer BE
AIDS Res Ther; 2010 Jul; 7():22. PubMed ID: 20618951
[TBL] [Abstract][Full Text] [Related]
32. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.
Rohan LC; Moncla BJ; Kunjara Na Ayudhya RP; Cost M; Huang Y; Gai F; Billitto N; Lynam JD; Pryke K; Graebing P; Hopkins N; Rooney JF; Friend D; Dezzutti CS
PLoS One; 2010 Feb; 5(2):e9310. PubMed ID: 20174579
[TBL] [Abstract][Full Text] [Related]
33. Use of lemon or lime juice douches in women in Jos, Nigeria.
Imade GE; Sagay AS; Onwuliri VA; Egah DZ; Potts M; Short RV
Sex Health; 2005; 2(4):237-9. PubMed ID: 16402671
[TBL] [Abstract][Full Text] [Related]
34. Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.
Buckheit KW; Furlan-Freguia C; Ham AS; Buckheit RW
Curr Top Med Chem; 2016; 16(10):1118-34. PubMed ID: 26324047
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization and preclinical formulation of a dual-action phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07) with potent anti-HIV and spermicidal activities.
D'Cruz OJ; Shih MJ; Yiv SH; Chen CL; Uckun FM
Mol Hum Reprod; 1999 May; 5(5):421-32. PubMed ID: 10338365
[TBL] [Abstract][Full Text] [Related]
36. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model.
Patton DL; Cosgrove Sweeney YT; Paul KJ
Sex Transm Dis; 2008 Oct; 35(10):889-97. PubMed ID: 18607310
[TBL] [Abstract][Full Text] [Related]
37. A 13-week subchronic intravaginal toxicity study of pokeweed antiviral protein in mice.
D'Cruz OJ; Waurzyniakt B; Uckun FM
Phytomedicine; 2004; 11(4):342-51. PubMed ID: 15185849
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model.
Kish-Catalone T; Pal R; Parrish J; Rose N; Hocker L; Hudacik L; Reitz M; Gallo R; Devico A
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):33-42. PubMed ID: 17263630
[TBL] [Abstract][Full Text] [Related]
39. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.
Greenhead P; Hayes P; Watts PS; Laing KG; Griffin GE; Shattock RJ
J Virol; 2000 Jun; 74(12):5577-86. PubMed ID: 10823865
[TBL] [Abstract][Full Text] [Related]
40. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.
Neurath AR; Strick N; Li YY
BMC Infect Dis; 2006 Oct; 6():150. PubMed ID: 17042959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
